Black Diamond Therapeutics, Inc. (BDTX)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, Black Diamond Therapeutics, Inc. reported revenue of $70.00M. The company was profitable, with a net margin of 32.0%. It held $143.01M in total assets against $30.80M in total liabilities.
Key ratios (FY2025)
17.9%
Operating margin
32.0%
Net margin
19.9%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70.00M | $0 | — | — | — | — | — | — | — |
| Operating Income | $12.52M | -$78.78M | -$86.46M | -$92.83M | -$126.87M | -$69.57M | -$29.33M | -$8.90M | — |
| Net Income | $22.37M | -$69.68M | -$82.44M | -$91.17M | -$125.60M | -$67.25M | -$35.26M | -$8.93M | — |
| EPS (Diluted) | $0.39 | $-1.27 | $-1.88 | $-2.52 | $-3.47 | $-2.05 | — | — | — |
| Total Assets | $143.01M | $122.64M | $158.57M | $156.25M | $247.68M | $329.67M | $158.29M | $51.83M | — |
| Total Liabilities | $30.80M | $39.35M | $41.83M | $40.56M | $51.78M | $21.91M | $4.88M | $6.60M | — |
| Shareholders' Equity | $112.21M | $83.28M | $116.74M | $115.69M | $195.90M | $307.76M | -$47.16M | -$15.54M | -$6.67M |
| Cash & Equivalents | $20.99M | $36.44M | $56.22M | $34.31M | $65.80M | $34.60M | $154.67M | $51.66M | — |
| Operating Cash Flow | $29.61M | -$62.30M | -$66.72M | -$85.08M | -$100.15M | -$52.15M | -$24.67M | -$8.45M | — |
| Capital Expenditures | — | $0 | $33.0K | $192.0K | $2.71M | $142.0K | $21.0K | $76.0K | — |
| Shares Outstanding | 57.14M | 56.64M | 51.65M | 36.43M | 36.23M | 36.08M | 2.24M | 2.17M | — |